- Investors & Media
- Investors & Media
- Contact Us
Kamada Achieves Worldwide Recognition:
Kamada is among the fastest growing companies in Europe according to the Deloitte Technology Fast 500™ index for the year 2012
This is in addition to winning 15th place among the fastest growing companies in Israel for the year 2012
This month Kamada joined the prestigious TA-100 index
An impressive achievement for the biopharmaceutical company Kamada – gaining the prestigious FAST 500 list: Kamada, specializing in the development, production and marketing of specialty life-saving therapeutics that are given by infusion, injection or inhalation, is proud to report it has been included in the Deloitte Technology Fast 500™ list. The list includes the 500 fastest growing companies in Europe, the Middle East and Africa (EMEA) in the fields of technology, media, communications, life sciences and cleantech. Ranking is based on the percentage yearly growth in income during the 5-year period 2007 to 2011. Kamada has grown by 311% throughout this period.
In Israel Kamada has been ranked in the 15th place according to the same index.
On December 15, 2012, Kamada joined the prestigious TA-100 Index, which represents the share prices of the 100 companies with the highest market value on the stock exchange.
Mr. David Tzur, Kamada's CEO (second from right), is opening the trading day at the Tel-Aviv Stock Exchance, 16.12.2012
In the past few years the company has shown consistently high growth as part of its successes in marketing GLASSIA, an AAT product given intravenously for the treatment of AAT deficiency, which is marketed in the US as part of its cooperation with Baxter International Inc. Continued rapid growth has enabled Kamada previously to raise its projected income for 2012 to a total of US$72 million. This follows the total income of US$59 million for 2011. Kamada foresees continued growth from sales of GLASSIA, which is marketed in six countries worldwide.
Kamada received a citation of excellence last year within the framework of the
National Quality and Excellence in the Business Sector Prize competition, honoring the late Prime Minister Yitzhak Rabin, and was thus the firstbiopharmateutic company in Israel to win this prize.
David Tsur, CEO of Kamada Ltd., stated that “we are very proud to be included in the prestigious Deloitte list of the fastest growing companies in Europe, the Middle East and Africa. As an Israeli biotechnology company, this achievement stands out
and is especially significant and we see ourselves as committed to a continued upward sales momentum. Our inclusion in this list constitutes additional international recognition of our company's accomplishments, commercially and scientifically."
About the Deloitte Technology Fast 500™ list for 2012
The process of ranking companies for the Technology Fast 500 list, conducted by Deloitte & Touche LLP, assigns scores to the fastest growing companies, both public and private, in Europe, the Middle East and Africa (EMEA) in the fields of technology, media, communications, life sciences and cleantech. The winners of the Technology Fast 500 prize are selected on the basis of their percentage annual growth during the period 2007–2011.
Kamada specializes in the development, manufacture, and marketing of specialty intravenous, injectable, or inhaled life-saving therapeutics. The company manufactures about ten drugs marketed in fifteen countries worldwide, and employs cutting-edge patented technology for protein purification and separation. Kamada has a line of unique products, including some in the advanced stages of clinical trials. Following the development of GLASSIA, which has FDA approval and is exclusively marketed in the US by Baxter, Kamada is developing its “next generation” product, which is currently in Phase II/III of a clinical trial: AAT administered by inhalation, for the treatment of Alpha-1 Antitrypsin deficiency, also known as hereditary emphysema. Kamada also completed Phase I/II of a clinical trial of intravenous AAT for treatment of Diabetes type-1, and is preparing for Phase II/III of a clinical trial in the US of an anti-rabies drug as part of its collaboration with the pharmaceutical company Kedrion SpA.
Visit our website www.kamada.com for additional information.